Summary
The pharmacokinetics and bioavailability of N-acetylcysteine (NAC) have been determined after its intravenous and oral administration to 6 healthy volunteers.
According to a randomized cross-over design each subject received NAC 200 mg i.v. and 400 mg p.o., and blood samples were collected for 30 h.
Reduced NAC had a volume of distribution (VSS) of 0.59 l·kg−1 and a plasma clearance of 0.84 l·h−1·kg−1. The terminal half-life after intravenous administration was 1.95 h. The oral bioavailability was 4.0%.
Based on total NAC concentration, its volume of distribution (VSS) was 0.47 l·kg−1 and its plasma clearance was 0.11 l·h−1·kg−1. The terminal half-life was 5.58 h after intravenous administration and 6.25 h after oral administration. Oral bioavailability of total NAC was 9.1%.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Sheffner AL (1963) The reduction in vitro in viscosity of mucoprotein solutions by a new mucolytic agent, N-acetyl-L-cysteine. Ann NY Acad Sci 106: 298–310
Millar A, Pavia D, Agnew JE, Lopez-Vidriero MT, Lauque D, Clarke W (1985) Effect of oral N-acetylcysteine on mucus clearance. Br J Dis Chest 79: 262–266
Grassi C, Morandini GC (1976) A controlled trial of intermittent oral acetylcysteine in the long-term treatment of chronic bronchitis. Eur J Clin Pharmacol 9: 393–396
Multicenter Study Group (1980) Long-term acetylcysteine in chronic bronchitis. A double-blind controlled study. Eur J Respir Dis 61 [Suppl 111]: 93–108
Boman G, Bäcker U, Larsson S, Melander B, Wåhlander L (1983) Oral acetylcysteine reduces exacerbation rate in chronic bronchitis: Report of a trial organized by the Swedish Society for Pulmonary Diseases. Eur J Respir Dis 64: 405–415
Prescott LF, Park J, Ballantyne A, Adriaenssens P, Proudfoot AT (1977) Treatment of paracetamol (acetaminophen) poisoning with N-acetalcysteine. Lancet 2: 432–437
Yarbro JW (ed) (1983) N-acetylcysteine (NAC): A significant chemoprotective adjunct. Proceedings of a symposium. Semin Oncol 10 [Suppl 1]: 1–92
Morgan LR, Holdiness MR, Gillen LE (1983) N-acetylcysteine: Its bioavailability and interactions with ifosfamide metabolites. Semin Oncol 10 [Suppl 1]: 56–61
Kågedal B, Källberg M, Mårtensson J (1984) Determination of non-protein-bound N-acetylcysteine in plasma by high-performance liquid chromatography. J Chromatogr 311: 170–175
Lewis PA, Woodward AJ, Maddock J (1985) Improved method for the determination of N-acetylcysteine in human plasma by high-performance liquid chromatography. J Chromatogr 327: 261–267
Cotgreave IA, Moldéus P (1987) Methodologies for the analysis of reduced and oxidised N-acetylcysteine in biological systems. Biopharm Drug Disp 8: 365–375
Johansson M, Westerlund D (1986) Determination of N-acetylcysteine, intact and oxidized in plasma by column liquid chromatography and post-column derivatization. J Chromatogr 385: 343–356
Sheffner AL, Medler EM, Bailey KR, Gallo DG, Mueller AJ, Sarett HP (1966) Metabolic studies with acetylcysteine. Biochem Pharmacol 15: 1523–1535
Rodenstein D, De Coster A, Gazzaniga A (1978) Pharmacokinetics of oral acetylcysteine: Absorption, binding and metabolism in patients with respiratory disorders. Clin Pharmacokinet 3: 247–254
Bonanomi L, Gazzaniga A (1980) Toxicological, pharmacokinetic and metabolic studies on acetylcysteine. Eur J Respir Dis 61 [Suppl 111]: 45–51
Borgström L, Kågedal B, Paulsen O (1986) Pharmacokinetics of N-acetylcystine in man. Eur J Clin Pharmacol 31: 217–222
Hakman M, Gabrielsson J (1986) Introduction to MAXFIT: A user's guide. Dept Biopharmaceutics and Pharmacokinetics, Uppsala University, Uppsala, Sweden
Sheiner LB, Beal SL (1985) Pharmacokinetic parameter estimates from several least squares procedures: superiority of extended least squares. J Pharmacokinet Biopharm 13: 185–201
Riegelman S, Collier P (1980) The application of statistical moment theory to the evaluation of in vivo dissolution time and absorption time. J Pharmacokinet Biopharm 8: 509–534
Gibaldi M, Perrier D (1982) Pharmacokinetics. Marcel Dekker, New York Basel
Cotgreave IA, Grafström RC, Moldéus P (1986) Modulation of pneumotoxicity by cellular glutathione and precursors. Bull Eur Physiopathol Respir 22: 263s-266s
Tee LBG, Boobis AR, Davies DS (1986) N-acetylcysteine for paracetamol overdose. Lancet 1: 331–332
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Olsson, B., Johansson, M., Gabrielsson, J. et al. Pharmacokinetics and bioavailability of reduced and oxidized N-acetylcysteine. Eur J Clin Pharmacol 34, 77–82 (1988). https://doi.org/10.1007/BF01061422
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF01061422